15 commercial payer policies list J9021. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
15 policies from 13 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J9021 |
|---|---|---|
| Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze) | Not recorded | Covered with conditionsInferred from policy title |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Asparagine Specific Enzymes (e.g., Rylaze, Asparlas, Oncaspar) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Oncology Medications | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Asparaginase Erwinia chrysanthemi (recombinant)-rywn (Rylaze) | Sep 30, 2021 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Cigna MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Erwinia Asparaginase (Rylaze); CP.PHAR.301 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Q4 - 2026 JHP MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Asparaginase erwinia chrysanthemi (recombinant) - rywn (Rylaze) - Minnesota Health Care Programs | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J9021 |
|---|---|---|
| Rylaze (asparaginase Erwinia chrysanthemi (recombinant)-rywn) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |